Sequencing Immunotherapy in the Third-line and Beyond Settin

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Related Keywords

Peter Martin , , Recent Updates , Follicular Lymphoma , Mantle Cell Lymphoma , Beyond Setting , Fl , Patient Preference , Cellular Therapy , Clinical Factor , Real World Data , Quality Of Life , Bispecific Antibody , Bendamustine , Cart Cell , Retrospective , Immunotherapy , Sequencing Therapy , Cart Cell Therapy ,